anti-myelin oligodendrocyte glycoprotein-IgG associated disorders
Conditions
Interventions
Healthy control group:N/A
Clinical phenotype group with MOG-IgG like correlation:N/A
Neurological diseases group with non MOG-IgG like clinical phenotypes:N/A
Sponsors
Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science & Technology
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: Age of first onset<18 years old, Complete medical examination data and treatment records (1) Healthy control group a. Including but not limited to healthy individuals from physical examination centers and pediatric care departments; b. People who have not been diagnosed with neuroimmune diseases; c. People who have not experienced fever, headache, mental disorders, sleep disorders, limb weakness, or inflammatory reactions recently. (2) Clinical phenotype group with MOG-IgG like correlation a. Patients with MOGAD clinical phenotype who comply with the "2020 Chinese Expert Consensus on the Diagnosis and Treatment of Diseases Related to Anti Myelinal Oligodendrocyte Glycoprotein Immunoglobulin G Antibodies"; b. Including atypical multiple sclerosis (MS), AQP4-IgG negative neuromyelitis pedigree disease (NMOSD), acute disseminated encephalomyelitis (ADEM), localized optic neuritis (ON), and transverse myelitis (TM); c. All patients are divided into initial MOGAD clinical phenotype patients and confirmed MOGAD patients undergoing treatment or recurrence. Confirmed patients undergoing treatment or recurrence must be in the disease progression stage rather than the remission stage; d. After the diagnosis of MOGAD, all patients need to record their medication status for treatment. During the medication period, they will be rechecked every month until 3 months, and serum samples will be taken. After treatment, a follow-up period of 6 to 30 months was conducted and serum samples were collected. (3) Neurological diseases group with non MOG-IgG like clinical phenotypes a. Patients with clinical phenotype of MOGAD that does not meet the consensus of Chinese experts on the diagnosis and treatment of MOGAD in 2020; b. Including classic MS, AQP4-IgG positive NMOSD, ON, and other central nervous system inflammatory demyelinating diseases (IDDS).
Exclusion criteria
Exclusion criteria: Exclusion criteria (1) The age of first onset is greater than 18 years old; (2) Not meeting the inclusion criteria for each group; (3) Patients have poor compliance and incomplete medical information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum MOG-IgG antibodies;Serum MOG-IgG antibodies; | — |
Countries
China
Contacts
Public ContactSun dan
Wuhan Children's Hospital of Tongji Medical College,Huazhong Universityof Science and Technology
Outcome results
None listed